Communiqué de presse conjoint avec l’Université de technologie Chalmers – 10 septembre 2015]

New research enables "tailored" diet advice – based on our personal gut microbiome – for persons who want to lose weight and reduce the risk of disease. Systems biologists at Chalmers University of Technology have for the first time successfully identified in detail how some of our most common intestinal bacteria interact during metabolism.

The researchers at Chalmers University of Technology have developed a mathematical calculation platform that makes it possible to predict how different patients will respond to a modified diet, depending on how their gut microbiome is composed.

Work has been conducted in cooperation in the context of the EU funded project Metacardis, coordinated by professor Karine Clement at Institute of Cardiometabolism and Nutrition (Ican, Pitié-Salpêtrière Hospital, Inserm/Sorbonne University) in Paris and also includes professor Fredrik Bäckhed at the University of Gothenburg.

Read more ...

Obesity is caused by many complex factors, some of which are yet unknown. Researchers from the French National Centre for Scientific Research (CNRS), Inserm, Pierre and Marie Curie University (UPMC) and Paris Descartes University, in collaboration with clinician researchers from the Paris Public Hospitals (AP-HP), have just shown that severe obesity is accompanied by inflammation of the small intestine and a strengthening of the immune defences in that area. This phenomenon reduces enterocyte[1] sensitivity to insulin and increases nutrient absorption, thus exacerbating the disease. This work, carried out at the Cordelier Research Centre (Inserm/UPMC/Paris Descartes University) and the Institute of Cardiometabolism and Nutrition (ICAN – Inserm/UPMC/AP-HP), is published on 18 June in the journal Cell Metabolism.

Read the full press release here

Press release – Inserm press room – The small intestine is involved in chronic inflammation in obese people

Also available in French

Paris, 22 November 2012

METACARDIS (Metagenomics in Cardiometabolic Diseases) is a European project coordinated by Inserm that aims to study the role of the gut microbiota in the development of cardiometabolic diseases (CMDs). Thanks to the support of the European Commission, fourteen partners in six European countries will work together over a five-year period to translate the results obtained with novel CMD diagnosis and treatment methods and pave the way for personalised medicine in CMDs. Researchers and clinicians from the Institute of Cardiometabolism and Nutrition (ICAN) will also be involved in the METACARDIS project.

Read more ...

Go to top
JSN Blank template designed by JoomlaShine.com

Our site uses cookies. We'll assume that you are OK with this if you browse further. To find out more about the cookies we use, see our Cookie Policy.

I accept cookies from this site